Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase Gα oxidation
2020 | journal article. A publication with affiliation to the University of Göttingen.
Jump to: Cite & Linked | Documents & Media | Details | Version history
Cite this publication
Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase Gα oxidation
Kolijn, D.; Pabel, S. ; Tian, Y.; Lódi, M.; Herwig, M.; Carrizzo, A. & Zhazykbayeva, S. et al. (2020)
Cardiovascular Research, 117(2) pp. 495-507. DOI: https://doi.org/10.1093/cvr/cvaa123
Documents & Media
Details
- Authors
- Kolijn, Detmar; Pabel, Steffen ; Tian, Yanna; Lódi, Mária; Herwig, Melissa; Carrizzo, Albino; Zhazykbayeva, Saltanat; Kovács, Árpád; Fülöp, Gábor Á; Falcão-Pires, Inês; Reusch, Peter H; Linthout, Sophie Van; Papp, Zoltán; van Heerebeek, Loek; Vecchione, Carmine; Maier, Lars S ; Ciccarelli, Michele; Tschöpe, Carsten; Mügge, Andreas; Bagi, Zsolt; Sossalla, Samuel ; Hamdani, Nazha
- Issue Date
- 2020
- Journal
- Cardiovascular Research
- ISSN
- 0008-6363
- eISSN
- 1755-3245
- Language
- English
